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Background
Viral resistance occurs with high frequency after single-
dose nevirapine (sdNVP) for PMTCT and alternative regi-
mens are urgently needed [1]. The objective of this study
was to evaluate the safety and resistance profile of a com-
bination of TDF (300 mg) and FTC (200 mg) in HIV-1
infected pregnant women and their newborns.
Methods
The TEmAA ANRS 12109 trial is an open label phase II
trial conducted in Ivory Coast, Cambodia and South
Africa. SdNVP (200 mg) and 2 tablets of TDF/FTC were
given to HIV-1-infected pregnant women at the beginning
of labor. One daily tablet of TDF/FTC was given for 7 days
postpartum. All women received zidovudine (ZDV, 300
mg BID) from the day of enrollment, between the 28th
and 38th week of gestation, until the beginning of labor.
All infants received sdNVP syrup on Day 2 (2 mg/kg) and
ZDV syrup (4mg/kg BID) for 7 days. Mothers and infants
were followed for two months. Serious adverse events
(SAEs) and HIV-1 infection status of the infants at 3 days
and 4 weeks of life were assessed using plasma RNA PCR.
Maternal HIV-1 RNA plasma viral load (VL) was per-
formed at enrolment, day 2 postpartum (PP) and at week
4 PP. Genotypic resistance tests were performed at week 4
PP.
Results
Thirty-eight HIV-1 infected pregnant women were
enrolled (19 in Abidjan, 12 in Phnom Penh and 7 in
Soweto): median age 27 years (interquartile range [IQR]:
23–30), median CD4 count 450 cells/mm3 (IQR: 314-
596) and median HIV-1 RNA VL 4.08 log copies/mL (IQR:
3.60-5.03). All women received TDF/FTC at a median of
4.9 hours before delivery (IQR: 3.0-8.2). Nine (24%) tran-
sient grade 3/4 biological events occurred in mothers dur-
ing postpartum follow-up (3 anaemia, 5 neutropenia and
1 elevation of liver enzymes). Among 39 livebirths (one
pair of twins), 9 infants had clinical SAEs (23%) and 2,
transient grade 3 anaemia (5%). Four children died (1
meningitis, 1 gastroenteritis with malnutrition, 1 intesti-
nal occlusion and 1 unexplained neurological disease)
while the other SAEs, with infectious origin (gastroenteri-
tis, bronchopneumonia, meningitis, conjunctivitis and
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neonatal sepsis), resolved. SAEs and deaths were unlikely
to be related to TDF/FTC. Two infants out of 38 tested at
4 weeks of life had detectable RNA plasma viral load, also
detectable at D3, suggesting in utero HIV infection (5.3%,
95% Confidence Interval [CI]: 0.6-17.8). Median mater-
nal HIV VL was 3.3 log10copies/ml at day 2 PP and 4.2
log10copies/ml at week 4 PP. No viral resistance muta-
tions to ZDV, NVP, FTC, and TDF were found in 19 moth-
ers tested at week 4 PP. Remaining tests are ongoing.
Conclusion
A TDF/FTC combination for PMTCT was well tolerated in
women and exposed newborns with no intrapartum HIV
transmission reported. Providing 7 days of additional PP
antiretroviral exposure with TDF/FTC immediately after
sdNVP+TDF/FTC extended the suppression of viral repli-
cation avoiding a PP exposure to sdNVP. The second step
of the trial will now look for the optimal neonatal dose of
TDF and FTC to introduce in this PMTCT regimen.
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